Prophylactic and therapeutic vaccination with carrier-bound Bet v 1 peptides lacking allergen-specific T cell epitopes reduces Bet v 1-specific T cell responses via blocking antibodies in a murine model for birch pollen allergy.
Bottom Line: The effects of peptide-specific and allergen-specific antibodies on T cell responses and allergic lung inflammation were studied using specific antibodies.Prophylactic and therapeutic vaccination of mice with the peptide vaccine induced Bet v 1-specific antibodies which suppressed Bet v 1-specific T cell responses and allergic lung inflammation.Vaccination with carrier-bound allergen-derived peptides lacking allergen-specific T cell epitopes induces allergen-specific IgG antibodies which suppress allergen-specific T cell responses and allergic lung inflammation.
Affiliation: Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.Show MeSH
Related in: MedlinePlus
Mentions: We furthermore tested the ability of the peptide vaccine to affect an already established allergen-specific T cell response in our mouse model. We found that after sensitization to Bet v 1, a robust Bet v 1-specific T cell response (i.e. SI's >10) was established (Fig.6a, S+/T−). This response was significantly reduced when mice were treated with the peptide vaccine (Fig.6a, S+/T+; P < 0.05). A relevant peptide-specific proliferation was observed in none of the mouse groups (Fig.6b). Mice treated with the peptide vaccine, but not mice who had not received the peptide vaccine, showed carrier-specific T cell responses (Fig.6c).
Affiliation: Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.